Joerg Thomas Hartmann
Research Subjects
Research Interests
Joerg Thomas Hartmann has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
- Carsten Bokemeyer
Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
18 shared publications L Kanz
11Abt. Hämatologie/Onkologie/Immunologie/Rheumatologie, Medizinische Klinik II, Eberhard-Karls-Universität, Tübingen, Germany
11 shared publicationsL. Kanz
11 shared publicationsLothar Kanz
Departments of aMedical Oncology/Hematology/Immunology/Rheumatology/Pulmonology, Eberhard-Karls-University, Medical Center, Tuebingen, Germany
7 shared publicationsCarsten Bokemeyer
6 shared publicationsR. Hofheinz
6 shared publications
Latest Publications
- Retraction
- 28 February 2012
- Published by Springer Nature in Current Oncology Reports
- Vol. 14 (2) , 220
Erratum to: New Drug Developments for Patients with Metastatic Soft Tissue Sarcoma
- 28 February 2012
- Published by Springer Nature in Current Oncology Reports
- Vol. 14 (2) , 220
RetractionErratum to: New Drug Developments for Patients with Metastatic Soft Tissue Sarcoma
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 3504
Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial.
3504 Background: 5-FU based CRT is regarded standard perioperative treatment in LARC. We report long-term data of a non-inferiority phase III trial investigating (neo-)adjuvant CRT with Cape in comparison with 5-FU. Methods: Patients (pts) aged ≥18 years with LARC UICC stages II or III were recruited into this two-arm, two-strata randomized phase-III trial (arm A: Cape, arm B: 5-FU; stratum [S] I: adjuvant, S II: neoadjuvant). Regimens: Arm A: CRT: 50.4 Gy + Cape 1,650 mg/m2 days 1-38 plus five courses of Cape 2,500 mg/m2 d 1-14, rep. d 22 (S I: 2 x Cape, CRT, 3 x Cape; S II: CRT, TME surgery, 5 x Cape). Arm B: CRT: 50.4 Gy + 5-FU 225 mg/m2 c.i. daily [S I] or 5-FU 1,000 mg/m2 c.i. d 1-5 and 29-33 [S II] plus 4 cycles of bolus 5-FU 500mg/m2 d 1-5, rep. d 29 (S I: 2 x 5-FU, CRT, 2 x 5-FU; S II: CRT, TME surgery, 4 x 5-FU). Primary endpoint was overall survival (OS), secondary endpoints comprised disease-free survival (DFS) and safety. Results: Of 401 randomized pts, 392 are evaluable (Arm A n=197, arm B n=195; S I n=231, S II n=161). Toxicity, treatment duration and downstaging in S II were reported at ASCO 2009. Briefly, pts receiving Cape had more hand-foot skin reactions (HFS), fatigue, and proctitis, while leukopenia was more frequent with 5-FU. Pts receiving Cape in S II had a significantly higher rate of ypN- tumors. At a median follow-up of 52 months, the local recurrence rate was equal (Cape 6%, 5-FU 7%, p=0.665), while significantly less pts developed distant metastases in the Cape arm (18.8% vs 27.7%; p=0.037). A total of 93 patients had died, 55 of whom in the 5-FU arm. Cape was non-inferior to 5-FU regarding 5-year OS (Cape 75.7% vs 5-FU 66.6%; p=0.0004). The test for superiority showed borderline significance in favor of Cape (p=0.053). 3-year DFS was significantly better with Cape (75.2% vs 66.6%; p=0.034). Cape pts developing HFS had better 3-year DFS (83.2%) and 5-year OS (91.4%) in comparison with the remaining pts (p=0.004 for DFS and p<0.0001 for OS). Conclusions: In view of the advantageous safety profile, an improved nodal-downstaging in neoadjuvant stratum and the favourable survival data Cape may replace 5-FU in the perioperative treatment of LARC.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 3504
Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial.
3504 Background: 5-FU based CRT is regarded standard perioperative treatment in LARC. We report long-term data of a non-inferiority phase III trial investigating (neo-)adjuvant CRT with Cape in comparison with 5-FU. Methods: Patients (pts) aged ≥18 years with LARC UICC stages II or III were recruited into this two-arm, two-strata randomized phase-III trial (arm A: Cape, arm B: 5-FU; stratum [S] I: adjuvant, S II: neoadjuvant). Regimens: Arm A: CRT: 50.4 Gy + Cape 1,650 mg/m2 days 1-38 plus five courses of Cape 2,500 mg/m2 d 1-14, rep. d 22 (S I: 2 x Cape, CRT, 3 x Cape; S II: CRT, TME surgery, 5 x Cape). Arm B: CRT: 50.4 Gy + 5-FU 225 mg/m2 c.i. daily [S I] or 5-FU 1,000 mg/m2 c.i. d 1-5 and 29-33 [S II] plus 4 cycles of bolus 5-FU 500mg/m2 d 1-5, rep. d 29 (S I: 2 x 5-FU, CRT, 2 x 5-FU; S II: CRT, TME surgery, 4 x 5-FU). Primary endpoint was overall survival (OS), secondary endpoints comprised disease-free survival (DFS) and safety. Results: Of 401 randomized pts, 392 are evaluable (Arm A n=197, arm B n=195; S I n=231, S II n=161). Toxicity, treatment duration and downstaging in S II were reported at ASCO 2009. Briefly, pts receiving Cape had more hand-foot skin reactions (HFS), fatigue, and proctitis, while leukopenia was more frequent with 5-FU. Pts receiving Cape in S II had a significantly higher rate of ypN- tumors. At a median follow-up of 52 months, the local recurrence rate was equal (Cape 6%, 5-FU 7%, p=0.665), while significantly less pts developed distant metastases in the Cape arm (18.8% vs 27.7%; p=0.037). A total of 93 patients had died, 55 of whom in the 5-FU arm. Cape was non-inferior to 5-FU regarding 5-year OS (Cape 75.7% vs 5-FU 66.6%; p=0.0004). The test for superiority showed borderline significance in favor of Cape (p=0.053). 3-year DFS was significantly better with Cape (75.2% vs 66.6%; p=0.034). Cape pts developing HFS had better 3-year DFS (83.2%) and 5-year OS (91.4%) in comparison with the remaining pts (p=0.004 for DFS and p<0.0001 for OS). Conclusions: In view of the advantageous safety profile, an improved nodal-downstaging in neoadjuvant stratum and the favourable survival data Cape may replace 5-FU in the perioperative treatment of LARC.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10084
Topoisomerase-based chemotherapy in adults with relapsed or refractory pediatric-type sarcoma: A retrospective analysis of the German AIO Sarcoma Group/BMBF SAREZ registry.
10084 Background: The objective was to assess the efficacy and safety of topoisomerase-based (TOPO) regimens in adult patients (pts) with pediatric-type sarcoma who failed induction chemotherapy. Methods: Pts with tumors belonging to the Ewing’s sarcoma family of tumors, osteosarcomas, embryonal and alveolar RMS, synovial or desmoplastic small round cell, refractory or relapsed after at least one prior induction chemotherapy, inoperable, locally advanced or metastatic, with progressive disease and adequate organ functions were treated with TOPO-inhibitor based regimens, consisting of topotecan, irinotecan, or etoposide combined with cyclophosphamide or carboplatin. Results: 45 pts, median age 29 yrs (16-59), 16 female, 29 male, had previously received induction treatment according to (inter)national study protocols. TOPO regimens consisted of topotecan + cyclo (n=36), single-agent irinotecan (2), etoposide + carbo (2) and topotecan + carbo (5), and were applied as 2nd-line treatment in 38 pts and ≥ 3rd-line in 7 pts. 27 pts had refractory disease (evidence of tumor progression within 6 mo of induction chemo); 10 pts had early relapses (6-24 mo) and 8 pts late relapse (> 24 mo). Pts received a median of 3 cycles (range, 1-6). Grade 3-4 CTC toxicity consisted mainly of hematologic side effects as well as nausea/vomiting and fatigue, 1 TRD occurred. Anti-tumor activity (n=43): 2 CR (4.7%), 5 PR (11.6%) and 12 SD (27.9%). Median duration of CR/PR/SD was 759d (1061-1362)/ 381 (100-1785)/160 (61-468), respectively. Pts with refractory disease had a lower chance to attain a response (CR/PR/SD) to treatment (p=0.001). The 3/6-mos PFR were 42% and 23% for all pts; however, 16% of pts achieved survival ≥ 24 mo. Factors associated with improved survival were response to treatment (2 CR) and PR + secondary surgery. Conclusions: The TOPO regimens with proven activity in pediatric pts show moderate effectivity in our adult pts with refractory or relapsed pediatric-type sarcoma. Adults with refractory small cell sarcoma appear to have a similar dismal outcome as pts with common adult-type histology, even though a subset of pts did achieve prolonged survival.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 10084
Topoisomerase-based chemotherapy in adults with relapsed or refractory pediatric-type sarcoma: A retrospective analysis of the German AIO Sarcoma Group/BMBF SAREZ registry.
10084 Background: The objective was to assess the efficacy and safety of topoisomerase-based (TOPO) regimens in adult patients (pts) with pediatric-type sarcoma who failed induction chemotherapy. Methods: Pts with tumors belonging to the Ewing’s sarcoma family of tumors, osteosarcomas, embryonal and alveolar RMS, synovial or desmoplastic small round cell, refractory or relapsed after at least one prior induction chemotherapy, inoperable, locally advanced or metastatic, with progressive disease and adequate organ functions were treated with TOPO-inhibitor based regimens, consisting of topotecan, irinotecan, or etoposide combined with cyclophosphamide or carboplatin. Results: 45 pts, median age 29 yrs (16-59), 16 female, 29 male, had previously received induction treatment according to (inter)national study protocols. TOPO regimens consisted of topotecan + cyclo (n=36), single-agent irinotecan (2), etoposide + carbo (2) and topotecan + carbo (5), and were applied as 2nd-line treatment in 38 pts and ≥ 3rd-line in 7 pts. 27 pts had refractory disease (evidence of tumor progression within 6 mo of induction chemo); 10 pts had early relapses (6-24 mo) and 8 pts late relapse (> 24 mo). Pts received a median of 3 cycles (range, 1-6). Grade 3-4 CTC toxicity consisted mainly of hematologic side effects as well as nausea/vomiting and fatigue, 1 TRD occurred. Anti-tumor activity (n=43): 2 CR (4.7%), 5 PR (11.6%) and 12 SD (27.9%). Median duration of CR/PR/SD was 759d (1061-1362)/ 381 (100-1785)/160 (61-468), respectively. Pts with refractory disease had a lower chance to attain a response (CR/PR/SD) to treatment (p=0.001). The 3/6-mos PFR were 42% and 23% for all pts; however, 16% of pts achieved survival ≥ 24 mo. Factors associated with improved survival were response to treatment (2 CR) and PR + secondary surgery. Conclusions: The TOPO regimens with proven activity in pediatric pts show moderate effectivity in our adult pts with refractory or relapsed pediatric-type sarcoma. Adults with refractory small cell sarcoma appear to have a similar dismal outcome as pts with common adult-type histology, even though a subset of pts did achieve prolonged survival.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e14624
Toxicogenomic profiling of fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) in advanced gastric cancer: A translational study of the German Arbeitsgemeinschaft Internistische Onkologie (AIO).
E14624 Background: To develop toxicogenomic profiles as predictors of clinically relevant grade 3/4 toxicities of chemotherapy in advanced gastric cancer (AGC). Methods: This randomized phase II study compared fluorouracil, leucovorin, oxaliplatin ± docetaxel (FLO vs. FLOT) in pts with AGC. As part of the study protocol blood samples of 143 pts were prospectively collected for DNA extraction and genotyping. 24 polymorphisms in 17 genes as part of the metabolism or transmembrane transport of the applied drugs, the folate metabolism or DNA repair were analyzed. Toxicity data were analysed using aggregated data and univariate Poisson regression to take into account varying therapy cycles. Multiple regression analysis was performed using non-aggregated data with repeated measures and generalized estimation equations in SAS Proc Genmod. Thereby, it was possible to include maximum information of each cycle per individual. The modified variance structure was modelled as exchangeable. Results: For clinical study data see abstract of Al-Batran et al. Univariate analyses revealed significant associations between various covariates (genotypes, clinical factors) and toxicities. Generalized estimation equations confirmed most of them in the multivariate setting. Significant associations were observed between neutropenia and treatment arm (p = 0.002), TS1394del6 (p = 0.016), GSTT1 (p = 0.028), GSTM1 (p = 0.023), ABCG2-C421A (p < 0.001), XRCC1-R399Q (p < 0.001), XPD-D312N (p = 0.004), XPD-K751Q (p = 0.007), SDF1-1'A (p = 0.033); between diarrhea and treatment arm (p = 0.001), ABCB1-G2677T (p = 0.032), XPD-K751Q (p = 0.013), MAD1-G558A (p = 0.015); between sensory neuropathy and performace status (p = 0.001), oxaliplatin dose (p = 0.009), XPD-K751Q (p = 0.029), OPRT-G213A (p = 0.003), SDF1-1'A (p = 0.035), MAD1-G558A (p = 0.017). Conclusions: Toxicogenomic profiling represents a powerful tool to identify potential relevant polymorphisms to predict chemotherapy induced toxicity in AGC pts. Validation of these markers is warranted and ongoing within the next clinical study of FLOT in AGC that has recently closed accruel with a total of 250 pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e14624
Toxicogenomic profiling of fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) in advanced gastric cancer: A translational study of the German Arbeitsgemeinschaft Internistische Onkologie (AIO).
E14624 Background: To develop toxicogenomic profiles as predictors of clinically relevant grade 3/4 toxicities of chemotherapy in advanced gastric cancer (AGC). Methods: This randomized phase II study compared fluorouracil, leucovorin, oxaliplatin ± docetaxel (FLO vs. FLOT) in pts with AGC. As part of the study protocol blood samples of 143 pts were prospectively collected for DNA extraction and genotyping. 24 polymorphisms in 17 genes as part of the metabolism or transmembrane transport of the applied drugs, the folate metabolism or DNA repair were analyzed. Toxicity data were analysed using aggregated data and univariate Poisson regression to take into account varying therapy cycles. Multiple regression analysis was performed using non-aggregated data with repeated measures and generalized estimation equations in SAS Proc Genmod. Thereby, it was possible to include maximum information of each cycle per individual. The modified variance structure was modelled as exchangeable. Results: For clinical study data see abstract of Al-Batran et al. Univariate analyses revealed significant associations between various covariates (genotypes, clinical factors) and toxicities. Generalized estimation equations confirmed most of them in the multivariate setting. Significant associations were observed between neutropenia and treatment arm (p = 0.002), TS1394del6 (p = 0.016), GSTT1 (p = 0.028), GSTM1 (p = 0.023), ABCG2-C421A (p < 0.001), XRCC1-R399Q (p < 0.001), XPD-D312N (p = 0.004), XPD-K751Q (p = 0.007), SDF1-1'A (p = 0.033); between diarrhea and treatment arm (p = 0.001), ABCB1-G2677T (p = 0.032), XPD-K751Q (p = 0.013), MAD1-G558A (p = 0.015); between sensory neuropathy and performace status (p = 0.001), oxaliplatin dose (p = 0.009), XPD-K751Q (p = 0.029), OPRT-G213A (p = 0.003), SDF1-1'A (p = 0.035), MAD1-G558A (p = 0.017). Conclusions: Toxicogenomic profiling represents a powerful tool to identify potential relevant polymorphisms to predict chemotherapy induced toxicity in AGC pts. Validation of these markers is warranted and ongoing within the next clinical study of FLOT in AGC that has recently closed accruel with a total of 250 pts. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 4579
Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.
4579 Background: The clinical relevance of germ cell tumor (GCT)-specific mRNA in peripheral blood stem cell (PBSC) harvests of germ-cell cancer patients undergoing high dose chemotherapy (HDCT) is controversial, possibly caused by inappropriate PCR conditions with inadequate sensitivity and specificity and small numbers of patients analyzed. We re-evaluated this issue in a large number of PBSC-products using a novel, GCT-specific quantitative PCR assay. Methods: PBSC-harvests of 140 patients treated with HDCT for relapsed or platinum-refractory GCT were tested for the presence contaminating tumor cells using a highly tumor cell-specific PCR protocol, which amplified the un-conserved 5’-untranslated region (5’UTR) of the germ cell tumor-specific alkaline phosphatase (gcap) gene, but not alkaline phosphatase mRNA, the latter being also present in the peripheral blood of healthy donors. In order to further avoid false positive results by amplification of pseudogenes, all mRNA's were subjected to repeated DNAse digestion before entering cDNA synthesis. Results: The novel 5’UTR gcap specific PCR enabled the quantitative detection of gcap mRNA with an unprecedented specificity and good sensitivity of 10^-5. A total of 140 PBSC apheresis products were screened, with sufficient mRNA and clinical data available from 113 patients. The median time to progression (TTP) was significantly shorter in patients with gcap-positive (n=66) as compared to gcap-negative PBSC products (n=44) (7.0 months versus not reached, p=0.01). With a median follow up of 8 years, the median overall survival was shorter in patients with gcap-positive as compared to gcap-negative PBSC products (20 month vs. not reached). This difference did not reach statistical significance (p=0.08). Conventional qualitative gcap-PCR failed to separate cohorts with different prognosis, underscoring the importance of a validated quantitative PCR assay to address the clinical impact of PBSC tumor cell contamination in GCT. Conclusions: A quantitative and gcap-specific 5’UTR PCR assay detecting gcap-mRNA in PBSC-harvests is a strong adverse prognostic factor in GCT patients undergoing HDCT. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 4579
Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.
4579 Background: The clinical relevance of germ cell tumor (GCT)-specific mRNA in peripheral blood stem cell (PBSC) harvests of germ-cell cancer patients undergoing high dose chemotherapy (HDCT) is controversial, possibly caused by inappropriate PCR conditions with inadequate sensitivity and specificity and small numbers of patients analyzed. We re-evaluated this issue in a large number of PBSC-products using a novel, GCT-specific quantitative PCR assay. Methods: PBSC-harvests of 140 patients treated with HDCT for relapsed or platinum-refractory GCT were tested for the presence contaminating tumor cells using a highly tumor cell-specific PCR protocol, which amplified the un-conserved 5’-untranslated region (5’UTR) of the germ cell tumor-specific alkaline phosphatase (gcap) gene, but not alkaline phosphatase mRNA, the latter being also present in the peripheral blood of healthy donors. In order to further avoid false positive results by amplification of pseudogenes, all mRNA's were subjected to repeated DNAse digestion before entering cDNA synthesis. Results: The novel 5’UTR gcap specific PCR enabled the quantitative detection of gcap mRNA with an unprecedented specificity and good sensitivity of 10^-5. A total of 140 PBSC apheresis products were screened, with sufficient mRNA and clinical data available from 113 patients. The median time to progression (TTP) was significantly shorter in patients with gcap-positive (n=66) as compared to gcap-negative PBSC products (n=44) (7.0 months versus not reached, p=0.01). With a median follow up of 8 years, the median overall survival was shorter in patients with gcap-positive as compared to gcap-negative PBSC products (20 month vs. not reached). This difference did not reach statistical significance (p=0.08). Conventional qualitative gcap-PCR failed to separate cohorts with different prognosis, underscoring the importance of a validated quantitative PCR assay to address the clinical impact of PBSC tumor cell contamination in GCT. Conclusions: A quantitative and gcap-specific 5’UTR PCR assay detecting gcap-mRNA in PBSC-harvests is a strong adverse prognostic factor in GCT patients undergoing HDCT. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 4013
5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
4013 Background: Elderly patients (pts) with esophagogastric cancer often do not receive effective 3-drug combination therapies due to tolerability concerns. This study evaluates a 2- versus a 3-drug combination in older adult pts with esophagogastric cancer. Methods: Pts ≥ 65 yrs of age with metastatic or locally advanced disease were stratified by ECOG PS, liver metastases, potential resectability, and pharmacogenetic risk (experimental) and were randomized to receive infusional 5-FU 2,600 mg/m2, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 (FLO) or the same regimen plus docetaxel 50 mg/m2 (FLOT), every 2 weeks. The primary endpoint was response rate (RR), having an 80% power to detect an improvement of RR from 30% to 50% using a p-level 0.1. Secondary endpoints included Toxicity, progression-free (PFS) and overall survival (OS), and time to treatment failure (TTF). Results: 143 pts (FLOT/FLO, 72/71) were randomized between Aug 2007 and Oct 2008 of whom 140 pts were eligible. Median age was 70 yrs and median ECOG was 1. 31% of pts had locally advanced potentially resectable disease (FLOT, 30%; FLO, 32%). Pts received a median of 8 cycles in both arms. FLOT was significantly superior to FLO regarding RR (49.3% vs. 27.5%, p = 0.018), TTF (4.4 vs. 3.8 months, p = 0.012) and PFS (9.1 vs. 6.7 months, p = 0.048). Median OS was 17.3 months with FLOT and 14.4 months with FLO (p = 0.275). FLOT was associated with significantly more NCI-CTC grade 1-4 alopecia (p < 0.001), neutropenia (p < 0.001), diarrhea (p = 0.009), and nausea (p = 0.041), but there were no differences between arms for complicated neutropenia, serious adverse events (SAEs), treatment durations, withdrawals/discontinuations for toxicity, or toxic deaths. Conclusions: FLOT improved efficacy in elderly pts with esophagogastric cancer. The increased toxicity did not result in intolerability in this specific population.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 4013
5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
4013 Background: Elderly patients (pts) with esophagogastric cancer often do not receive effective 3-drug combination therapies due to tolerability concerns. This study evaluates a 2- versus a 3-drug combination in older adult pts with esophagogastric cancer. Methods: Pts ≥ 65 yrs of age with metastatic or locally advanced disease were stratified by ECOG PS, liver metastases, potential resectability, and pharmacogenetic risk (experimental) and were randomized to receive infusional 5-FU 2,600 mg/m2, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 (FLO) or the same regimen plus docetaxel 50 mg/m2 (FLOT), every 2 weeks. The primary endpoint was response rate (RR), having an 80% power to detect an improvement of RR from 30% to 50% using a p-level 0.1. Secondary endpoints included Toxicity, progression-free (PFS) and overall survival (OS), and time to treatment failure (TTF). Results: 143 pts (FLOT/FLO, 72/71) were randomized between Aug 2007 and Oct 2008 of whom 140 pts were eligible. Median age was 70 yrs and median ECOG was 1. 31% of pts had locally advanced potentially resectable disease (FLOT, 30%; FLO, 32%). Pts received a median of 8 cycles in both arms. FLOT was significantly superior to FLO regarding RR (49.3% vs. 27.5%, p = 0.018), TTF (4.4 vs. 3.8 months, p = 0.012) and PFS (9.1 vs. 6.7 months, p = 0.048). Median OS was 17.3 months with FLOT and 14.4 months with FLO (p = 0.275). FLOT was associated with significantly more NCI-CTC grade 1-4 alopecia (p < 0.001), neutropenia (p < 0.001), diarrhea (p = 0.009), and nausea (p = 0.041), but there were no differences between arms for complicated neutropenia, serious adverse events (SAEs), treatment durations, withdrawals/discontinuations for toxicity, or toxic deaths. Conclusions: FLOT improved efficacy in elderly pts with esophagogastric cancer. The increased toxicity did not result in intolerability in this specific population.
- Top Cited Papers
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 10 (5) , 470-481
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various malignancies. Imatinib was the first to be introduced into clinical oncology, and it was followed by drugs such as gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib. Although they share the same mechanism of action, namely competitive ATP inhibition at the catalytic binding site of tyrosine kinase, they differ from each other in the spectrum of targeted kinases, their pharmacokinetics as well as substance-specific adverse effects. With variations from drug to drug, tyrosine kinase inhibitors cause skin toxicity, including folliculitis, in more than 50% of patients. Among the tyrosine kinase inhibitors that are commercially available as yet, the agents that target EGFR, erlotinib and gefitinib, display the broadest spectrum of adverse effects on skin and hair, including folliculitis, paronychia, facial hair growth, facial erythema, and varying forms of frontal alopecia. In contrast, folliculitis is not common during administration of sorafenib and sunitinib, which target VEGFR, PDGFR, FLT3, and others, whereas both agents have been associated with subungual splinter hemorrhages. Periorbital edema is a common adverse effect of imatinib. Besides the haematological side effects of most of TKIs like anemia, thrombopenia and neutropenia, the most common extraheamatologic adverse effects are edema, nausea, hypothyroidism, vomiting and diarrhea. Regarding possible long term effects, recently cardiac toxicity with congestive heart failure is under debate in patients receiving imatinib and sunitinib therapy; however, this observation was probably relate to patients selection, although, TKIs overall appear to be a very well tolerated drug class.
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 10 (5) , 470-481
Top Cited PapersTyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various malignancies. Imatinib was the first to be introduced into clinical oncology, and it was followed by drugs such as gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib. Although they share the same mechanism of action, namely competitive ATP inhibition at the catalytic binding site of tyrosine kinase, they differ from each other in the spectrum of targeted kinases, their pharmacokinetics as well as substance-specific adverse effects. With variations from drug to drug, tyrosine kinase inhibitors cause skin toxicity, including folliculitis, in more than 50% of patients. Among the tyrosine kinase inhibitors that are commercially available as yet, the agents that target EGFR, erlotinib and gefitinib, display the broadest spectrum of adverse effects on skin and hair, including folliculitis, paronychia, facial hair growth, facial erythema, and varying forms of frontal alopecia. In contrast, folliculitis is not common during administration of sorafenib and sunitinib, which target VEGFR, PDGFR, FLT3, and others, whereas both agents have been associated with subungual splinter hemorrhages. Periorbital edema is a common adverse effect of imatinib. Besides the haematological side effects of most of TKIs like anemia, thrombopenia and neutropenia, the most common extraheamatologic adverse effects are edema, nausea, hypothyroidism, vomiting and diarrhea. Regarding possible long term effects, recently cardiac toxicity with congestive heart failure is under debate in patients receiving imatinib and sunitinib therapy; however, this observation was probably relate to patients selection, although, TKIs overall appear to be a very well tolerated drug class.
- 3 April 2009
- Published by Springer Nature in Der Onkologe
- Vol. 15 (4) , 389-397
Neoadjuvante Chemotherapie des lokalisierten Weichteilsarkoms
- 3 April 2009
- Published by Springer Nature in Der Onkologe
- Vol. 15 (4) , 389-397
Neoadjuvante Chemotherapie des lokalisierten Weichteilsarkoms
- 24 January 2009
- Published by Springer Nature in Der Onkologe
- Vol. 15 (2) , 163-168
Haut- und Schleimhauttoxizität neuer Substanzen
- 24 January 2009
- Published by Springer Nature in Der Onkologe
- Vol. 15 (2) , 163-168
Haut- und Schleimhauttoxizität neuer Substanzen
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 4544
Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO
4544 Background: MMP-9 has been implicated in invasion and metastasis of cancer, but little is known about its prognostic role in patients (pts) with metastatic gastric cancer undergoing chemotherapy. Methods: Tumor samples from pts who received first-line 5-fluorouracil, leucovorin and platinum for metastatic gastric cancer within a phase III trial of the AIO were prospectively collected and analyzed. The expression of MMP-9 mRNA was assessed by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Moreover, EGFR, pAKT, pMAPK, HER2/neu, Ki-67, CD8+ cell and macrophage accumulation and VEGF-A were evaluated (by qRT-PCR and/or immunohistochemistry). Results: Overall, 288 samples from 168 out of 220 pts enrolled were analyzed for at least one of the marker. 158 samples of 109 pts have been assessed for MMP9 mRNA so far; 96 pts were eligible for the analysis. In this cohort, increased MMP-9 levels were strongly associated with resistance to chemotherapy and shorter progression-free and overall survival. At the cut-off with the highest predictive value, the rate of disease progression as best response associated with elevated MMP9 expression was 50% (versus 22.4%; fisher’s test p=0.0276) and the relative hazard ratio for death was 2.653 (95% CI, 2.060 - 9.268); log rank p<.0001). The prognostic value for survival was maintained when data were categorized according to the median (p=.024) or quartile (p=0.004) distributions for MMP-9 expression. Interestingly, elevated MMP-9 levels were associated with more lymph node and peritoneal and less liver involvement and correlated with increased intratumoral VEGF-A levels. Other correlative analyses will be presented at the meeting. Conclusions: The association of MMP-9 expression with poor response to chemotherapy, and shorter survival suggests that MMP-9 is linked not only to early invasion and metastases formation, but also to an aggressive clinical course in metastatic disease. Thus, MMP-9 mRNA expression levels may represent a valuable marker for novel anti-protease treatment strategies.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 4544
Association of elevated matrix metalloproteinase-9 (MMP-9) mRNA expression levels with resistance to chemotherapy and survival in patients with metastatic gastric cancer receiving first-line chemotherapy: Results from the FLO versus FLP gastric cancer phase III trial of the AIO
4544 Background: MMP-9 has been implicated in invasion and metastasis of cancer, but little is known about its prognostic role in patients (pts) with metastatic gastric cancer undergoing chemotherapy. Methods: Tumor samples from pts who received first-line 5-fluorouracil, leucovorin and platinum for metastatic gastric cancer within a phase III trial of the AIO were prospectively collected and analyzed. The expression of MMP-9 mRNA was assessed by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Moreover, EGFR, pAKT, pMAPK, HER2/neu, Ki-67, CD8+ cell and macrophage accumulation and VEGF-A were evaluated (by qRT-PCR and/or immunohistochemistry). Results: Overall, 288 samples from 168 out of 220 pts enrolled were analyzed for at least one of the marker. 158 samples of 109 pts have been assessed for MMP9 mRNA so far; 96 pts were eligible for the analysis. In this cohort, increased MMP-9 levels were strongly associated with resistance to chemotherapy and shorter progression-free and overall survival. At the cut-off with the highest predictive value, the rate of disease progression as best response associated with elevated MMP9 expression was 50% (versus 22.4%; fisher’s test p=0.0276) and the relative hazard ratio for death was 2.653 (95% CI, 2.060 - 9.268); log rank p<.0001). The prognostic value for survival was maintained when data were categorized according to the median (p=.024) or quartile (p=0.004) distributions for MMP-9 expression. Interestingly, elevated MMP-9 levels were associated with more lymph node and peritoneal and less liver involvement and correlated with increased intratumoral VEGF-A levels. Other correlative analyses will be presented at the meeting. Conclusions: The association of MMP-9 expression with poor response to chemotherapy, and shorter survival suggests that MMP-9 is linked not only to early invasion and metastases formation, but also to an aggressive clinical course in metastatic disease. Thus, MMP-9 mRNA expression levels may represent a valuable marker for novel anti-protease treatment strategies.